(Q44780863)

6 December 2017

title

Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells (English)

1 reference

6 December 2017

M-C Wagner

1

1 reference

6 December 2017

M Dziadosz

2

1 reference

6 December 2017

J V Melo

3

1 reference

6 December 2017

F Heidel

4

1 reference

6 December 2017

T Fischer

5

1 reference

6 December 2017

D B Lipka

6

1 reference

6 December 2017

publication date

12 December 2012

1 reference

6 December 2017

1 reference

6 December 2017

volume

27

1 reference

6 December 2017

issue

7

1 reference

6 December 2017

page(s)

1567-1570

1 reference

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.364

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.364

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.364

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.364

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.364

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.364

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.364

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.364

Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.364

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.364

Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.364

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.364

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.364

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.364

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.364

inferred from DOI database lookup

7 January 2021

based on heuristic

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.364

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2012.364

1 reference

Dimensions Publication ID

6 December 2017

1009138895

0 references

1 reference